The Envita Medical Center lawsuit that draws the most current attention is Crone v. Envita Medical Centers LLC, a medical malpractice case filed in Maricopa County Superior Court in September 2023. It is not the only regulatory or legal problem attached to the Scottsdale clinic. The U.S. Food and Drug Administration issued Envita a warning letter in 2006 for administering an unapproved biological drug to patients, and a 2023 peer-reviewed study flagged the clinic’s paid social media advertising for making cancer-cure claims researchers described as scientifically unsupported.
The Crone Malpractice Lawsuit
Vaughn Crone filed suit on September 14, 2023, against Envita Medical Centers LLC, a related entity called E I R LLC, and Dr. David Medina. Attorney Craig A. Knapp brought the case, which was classified as not subject to mandatory arbitration, meaning the claimed damages exceed Arizona’s arbitration threshold.1Trellis Law. Crone vs Envita Medical Centers LLC et al.
Dr. Medina has served as Medical Director at Envita Interventional Radiology in Glendale, Arizona, since 2021.2Marquis Top Doctors. David Medina The specific allegations in the Crone complaint and the current status of the case are not available in the public records reviewed.
The 2006 FDA Warning Letter
On June 14, 2006, the FDA issued a warning letter to Dino Prato, listed as Office Administrator of Envita Natural Medical Centers of America, following an inspection conducted on March 1 of that year. Inspectors found that Envita had been manufacturing a biological product using a procedure it called “Long-Term 4NKT Cultures” and administering it to patients to treat illnesses including cancer.3FDA/CIRCARE. FDA Warning Letter to Envita Natural Medical Centers
The agency determined the cell culture product was an unapproved biological drug under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. Envita held no Biologics License Application, no New Drug Application, and no Investigational New Drug application, each of which is required before administering such a product to patients. The FDA also found the product misbranded: its own label read “for research use only” and “not for use in diagnostic or therapeutic procedures,” yet the clinic was using it clinically.3FDA/CIRCARE. FDA Warning Letter to Envita Natural Medical Centers
The letter warned that failure to correct the violations could result in injunction or clinical investigator disqualification proceedings. Public records reviewed do not indicate whether Envita complied, whether the FDA took further enforcement action, or whether the 4NKT product was discontinued.
Scrutiny of Envita’s Cancer-Cure Advertising
A 2023 peer-reviewed study indexed in PubMed Central analyzed paid advertisements for alternative cancer treatments running on Facebook, Instagram, and Messenger during one week in December 2021. Envita was one of 11 clinics identified and accounted for six of the 310 ads reviewed.4PMC/National Library of Medicine. Advertising Alternative Cancer Treatments and Approaches on Meta Social Media Platforms
Roughly a quarter of the ads across all 11 clinics contained direct claims that treatments could cure cancer or prolong life. The researchers singled out an Envita ad featuring a patient testimonial that read, “I came in here with stage 4 colorectal cancer, [and] I’m leaving cancer free.” The authors classified this kind of advertising as marketing “scientifically unsupported cancer treatments” that “exploited the hope of patients with terminal and poor prognoses.”4PMC/National Library of Medicine. Advertising Alternative Cancer Treatments and Approaches on Meta Social Media Platforms
What Envita Treats and How the Business Is Structured
Envita was founded in 2001 by Dino Prato, a naturopathic doctor who serves as CEO.5DrDinoPrato.com. Dr. Dino Prato Its signature protocol is Genetically Targeted Fractionated Chemotherapy, or GTFC, which uses lower doses of multiple chemotherapy drugs selected through molecular profiling of a patient’s tumor. The clinic pairs GTFC with customized immunotherapy, nutritional interventions, oxidative medicine, and what it calls “adjuvant natural agents.” Envita positions these treatments as options for patients who have exhausted standard oncology, and it explicitly departs from the National Comprehensive Cancer Network guidelines followed by conventional cancer centers.6SCIRP. Envita Medical Centers Treatment Study
On its own website, Envita acknowledges that GTFC “is still in its infancy” and that there are “skeptics that feel that the data is insufficient.” It cites its own clinical experience and patient anecdotes in support.7Envita Medical Centers. What Is Genetically Targeted Fractionated Chemotherapy
The GTFC drugs themselves are compounded by Vertisis Custom Pharmacy, a 503A compounding pharmacy Prato founded in January 2016. Vertisis is listed by the Better Business Bureau as a related business to Envita Medical Centers LLC.8BBB. Vertisis Custom Pharmacy LLC BBB Business Profile When Envita prescribes its proprietary chemotherapy, the pharmacy preparing those drugs is controlled by the same person who owns the clinic.
The Hagedorn Case and the Cost of Treatment
Envita drew wider public attention through the death of U.S. Representative Jim Hagedorn of Minnesota. After the Mayo Clinic told Hagedorn it had exhausted options for his kidney cancer, he traveled to Envita’s Scottsdale facility in January 2022 for treatment estimated at $55,000 over three months. His congressional health insurance did not cover it.9Star Tribune. Late Rep. Jim Hagedorn’s Family Sues Widow for Medical Expenses
His mother and stepfather took out a $25,000 home equity loan to help pay, and his sister put $10,000 on a credit card. Hagedorn died on February 17, 2022, before the treatments were completed, and Envita refunded $14,617 to the family.10Twin Cities Pioneer Press. Court Orders Jennifer Carnahan to Repay Late Husband’s Family Members for Help With Cancer Treatment Envita was not a defendant in the subsequent lawsuits, which were between Hagedorn’s family members and his widow over who owed whom for the treatment costs. The case is worth knowing because it shows the financial exposure a family can take on when pursuing uninsured alternative cancer treatment at the clinic.